Zevra Therapeutics, Inc. Announces CFO Transition

Core Points - Zevra Therapeutics, Inc. announced the resignation of its Chief Financial Officer, R. LaDuane Clifton, effective December 31, 2025, to pursue other professional opportunities [1][2] - Clifton has been with the company since 2015, providing leadership and guidance during its transition from a development stage to a commercial-stage company focused on rare diseases [2] - The company is currently searching for a new Chief Financial Officer to continue its growth trajectory [2] Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company dedicated to addressing unmet needs in the treatment of rare diseases [3] - The company's mission is to deliver life-changing therapeutics to individuals living with rare diseases through innovative, data-driven development and commercialization strategies [3] Expanded Access Programs - Zevra Therapeutics offers expanded access programs, which are subject to the company's policy and the laws of each jurisdiction [4]